Nakil sonrası diabetes mellitus

Yıl 2016, Cilt: 1 Sayı: 1, 35 - 42, 01.02.2016

Ayşe Sinangil Vedat Çelik Soykan Barlas Ebru Asmaz Barış Akın Tevfik Ecder

Öz

Nakil sonrası diabetes mellitus (DM), solid organ nakilleri sonrasında sık rastlanan ve ciddi bir komplikasyondur. Böbrek nakil alıcılarında %4-40 oranında nakil sonrası DM oluştuğu bildirilmiştir. Yıllar içerisinde kullanılan farklı sınıflandırma sistemleri ve tanımlamalardan dolayı böbrek nakli sonrası gelişen nakil sonrası DM'nin gerçek insidansını belirlemek zordur. Nakil sonrası DM gelişen böbrek nakil alıcılarında fatal ve nonfatal kardiyovasküler olaylar ve enfeksiyon, azalmış hasta sağkalımı, graft rejeksiyonu, akselere greft fonksiyon kayıpları gibi diğer yan etkiler diyabet gelişmeyenlere göre daha sık gözlenmektedir. Erken tanı ve tanı sonrası nakil sonrası DM’ye yönelik özel antihiperglisemik tedavinin uygulanması, glisemik kontrol için gerekli olup nakil sonrası mortalite ve morbiditenin anlamlı ölçüde azalmasına katkı sağlamaktadır. Bu derlemede nakil sonrası DM’nin güncel tanısı, solid organ nakli sonrası prevalansı, potansiyel patogenetik mekanizmalar, risk faktörleri ve güncel tedavi yöntemleri literatür eşliğinde sunulmuştur.

Anahtar Kelimeler

Diabetes mellitus, böbrek nakli, nakil sonrası diabetes mellitus

Kaynakça

• Overbeck I, Bartels M, Decker O, Harms J, Hauss J, Fangmann J. Changes in quality of life after renal transplantation. Transplant Proc 2005;37:1618-21.
• Rabbat CG, Thorpe KE, Russell JD, Churchill DN. Comparison of mortality risk for dialysis patients and cadaveric first renal transplant recipients in Ontario, Canada. J Am Soc Nephrol 2000;11:917-22.
• Ojo AO, Hanson JA, Meier-Kriesche H, Okechukwu CN, Wolfe RA, Leichtman AB, et al. Survival in recipients of marginal cadaveric donor kidneys compared with other recipients and wait-listed transplant candidates. J Am Soc Nephrol 2001;12:589-97.
• Meier-Kriesche HU, Port FK, Ojo AO, Rudich SM, Hanson JA, Cibrik DM, et al. Effect of waiting time on renal transplant outcome. Kidney Int 2000;58:1311-7.
• Brunkhorst R, Lufft V, Dannenberg B, Kliem V, Tusch G, Pichlmayr R. Improved survival in patients with type 1 diabetes mellitus after renal transplantation compared with hemodialysis: a case-control study. Transplantation 2003;76:115-9.
• Merion RM, Ashby VB, Wolfe RA, Distant DA, Hulbert-Shearon TE, Metzger RA, et al. Deceased- donor characteristics and the survival benefit of kidney transplantation. JAMA 2005;294:2726-33.
• Franke GH, Reimer J, Philipp T, Heemann U. Aspects of quality of life through end-stage renal disease. Qual Life Res 2003;12:103-15.
• Jofré R, López-Gómez JM, Moreno F, Sanz-Guajardo D, Valderrábano F. Changes in quality of life after renal transplantation. Am J Kidney Dis 1998;32:93-100.
• Overbeck I, Bartels M, Decker O, Harms J, Hauss J, Fangmann J. Changes in quality of life after renal transplantation. Transplant Proc 2005;37:1618-21.
• Balaska A, Moustafellos P, Gourgiotis S, Pistolas D, Hadjiyannakis E, Vougas V, et al. Changes in health- related quality of life in Greek adult patients 1 year after successful renal transplantation. Exp Clin Transplant 2006;4:521-4.
• Gallon LG, Leventhal JR, Kaufman DB. Pretransplant evaluation of renal transplant candidates. Semin Nephrol 2002;22:515-25.
• Neylan JF, Sayegh MH, Coffman TM, Danovitch GM, Krensky AM, Strom TB, et al. The allocation of cadaver kidneys for transplantation in the United States: consensus and controversy. ASN Transplant Advisory Group. American Society of Nephrology. J Am Soc Nephrol 1999;10:2237-43.
• Pham PT, Pham PM, Pham SV, Pham PA, Pham PC. New onset diabetes after transplantation (NODAT): an overview. Diabetes Metab Syndr Obes 2011;4:175-86.
• Kesiraju S, Paritala P, Rao Ch UM, Sahariah S. New onset of diabetes after transplantation - an overview of epidemiology, mechanism of development and diagnosis. Transpl Immunol 2014;30:52-8.
• Baid S, Cosimi AB, Farrell ML, Schoenfeld DA, Feng S, Chung RT, et al. Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation 2001;72:1066-72.
• Knobler H, Stagnaro-Green A, Wallenstein S, Schwartz M, Roman SH. Higher incidence of diabetes in liver transplant recipients with hepatitis C. J Clin Gastroenterol 1998;26:30-3.
• Bigam DL, Pennington JJ, Carpentier A, Wanless IR, Hemming AW, Croxford R, et al. Hepatitis C-related cirrhosis: a predictor of diabetes after liver transplantation. Hepatology 2000;32:87-90.
• Davidson J, Wilkinson A, Dantal J, Dotta F, Haller H, Hernández D, et al. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation 2003;75:3-24.
• Ye X, Kuo HT, Sampaio MS, Jiang Y, Bunnapradist S. Risk factors for development of new-onset diabetes mellitus after transplant in adult lung transplant recipients. Clin Transplant 2011;25:885-91.
• Sharif A, Moore RH, Baboolal K. The use of oral glucose tolerance tests to risk stratify for new-onset diabetes after transplantation: An underdiagnosed phenomenon. Transplantation 2006;82:1667-72.
• Bergrem HA, Valderhaug TG, Hartmann A, Hjelmesaeth J, Leivestad T, Bergrem H, et al. Undiagnosed diabetes in kidney transplant candidates: a case-finding strategy. Clin J Am Soc Nephrol 2010;5:616-22.
• Davidson J, Wilkinson A, Dantal J, Dotta F, Haller H, Hernández D, et al. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation 2003;75:3-24.
• Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003;26:5-20.
• American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010;33(Supp. 1):S62-9.
• Sharif A, Hecking M, de Vries AP, Porrini E, Hornum M, Rasoul-Rockenschaub S, et al. Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions. Am J Transplant 2014;14:1992-2000.
• Chakkera HA, Knowler WC, Devarapalli Y, Weil EJ, Heilman RL, Dueck A, et al. Relationship between inpatient hyperglycemia and insulin treatment after kidney transplantation and future new onset diabetes mellitus. Clin J Am Soc Nephrol 2010;5:1669-75.
• Fridlyand LE, Philipson LH. Does the glucose-dependent insulin secretion mechanism itself cause oxidative stress in pancreatic beta-cells? Diabetes 2004;53:1942-8.
• Heit JJ, Apelqvist AA, Gu X, Winslow MM, Neilson JR, Crabtree GR, et al. Calcineurin/NFAT signalling regulates pancreatic beta-cell growth and function. Nature 2006;443:345-9.
• Nam JH, Mun JI, Kim SI, Kang SW, Choi KH, Park K, et al. beta-Cell dysfunction rather than insulin resistance is the main contributing factor for the development of postrenal transplantation diabetes mellitus. Transplantation 2001;71:1417-23.
• Woodward RS, Schnitzler MA, Baty J, Lowell JA, Lopez- Rocafort L, Haider S, et al. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant 2003;3:590-8.
• Torres-Romero LF, Santiago-Delpín EA, de Echegaray S, Solis DR, Rodriguez-Trinidad AT, Gonzalez-Caraballo ZA, et al. HLA is not predictive of posttransplant diabetes mellitus. Transplant Proc 2006;38:914-5.
• Bamoulid J, Courivaud C, Deschamps M, Mercier P, Ferrand C, Penfornis A, et al. IL-6 promoter polymorphism -174 is associated with new-onset diabetes after transplantation. J Am Soc Nephrol 2006;17:2333-40.
• Ghisdal L, Baron C, Le Meur Y, Lionet A, Halimi JM, Rerolle JP, et al. TCF7L2 polymorphism associates with new-onset diabetes after transplantation. J Am Soc Nephrol 2009;20:2459-67.
• Ramachandran A, Snehalatha C, Latha E, Vijay V, Viswanathan M. Rising prevalence of NIDDM in an urban population in India. Diabetologia 1997;40:232-7.
• Porrini E, Delgado P, Bigo C, Alvarez A, Cobo M, Checa MD, et al. Impact of metabolic syndrome on graft function and survival after cadaveric renal transplantation. Am J Kidney Dis 2006;48:134-42.
• Yates CJ, Fourlanos S, Hjelmesaeth J, Colman PG, Cohney SJ. New-onset diabetes after kidney transplantation- changes and challenges. Am J Transplant 2012;12:820-8.
• Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003;3:178-85.
• Shah T, Kasravi A, Huang E, Hayashi R, Young B, Cho YW, et al. Risk factors for development of new-onset diabetes mellitus after kidney transplantation. Transplantation 2006;82:1673-6.
• Fabrizi F, Martin P, Dixit V, Bunnapradist S, Kanwal F, Dulai G. Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: meta-analysis of clinical studies. Am J Transplant 2005;5:2433-40.
• Finni PE, Souza ER, Rioja S, Ventura S, Starling P, Almeida JR, et al. Is hepatitis C a risk factor to posttransplant diabetes mellitus after renal transplantation in patients using tacrolimus? Transplant Proc 2004;36:884-5.
• Lehr H, Jao S, Waltzer WC, Anaise D, Rapaport FT. Cytomegalovirus-induced diabetes mellitus in a renal allograft recipient. Transplant Proc 1985;17:2152-4.
• Hjelmesaeth J, Müller F, Jenssen T, Rollag H, Sagedal S, Hartmann A. Is there a link between cytomegalovirus infection and new-onset posttransplantation diabetes mellitus? Potential mechanisms of virus induced beta-cell damage. Nephrol Dial Transplant 2005;20:2311-5.
• Luan FL, Steffick DE, Ojo AO. New-onset diabetes mellitus in kidney transplant recipients discharged on steroid-free immunosuppression. Transplantation 2011;91:334-41.
• Redmon JB, Olson LK, Armstrong MB, Greene MJ, Robertson RP. Effects of tacrolimus (FK506) on human insulin gene expression, insulin mRNA levels, and insulin secretion in HIT-T15 cells. J Clin Invest 1996;98:2786-93.
• Herold KC, Nagamatsu S, Buse JB, Kulsakdinun P, Steiner DF. Inhibition of glucose-stimulated insulin release from beta TC3 cells and rodent islets by an analog of FK506. Transplantation 1993;55:186-92.
• van Hooff JP, Christiaans MH, van Duijnhoven EM. Evaluating mechanisms of post-transplant diabetes mellitus. Nephrol Dial Transplant 2004;19:8-12.
• Duijnhoven EM, Boots JM, Christiaans MH, Wolffenbuttel BH, Van Hooff JP. Influence of tacrolimus on glucose metabolism before and after renal transplantation: a prospective study. J Am Soc Nephrol 2001;12:583-8.
• Menegazzo LA, Ursich MJ, Fukui RT, Rocha DM, Silva ME, Ianhez LE, et al. Mechanism of the diabetogenic action of cyclosporin A. Horm Metab Res 1998;30:663-7.
• Shah T, Kasravi A, Huang E, Hayashi R, Young B, Cho YW, et al. Risk factors for development of new-onset diabetes mellitus after kidney transplantation. Transplantation 2006;82:1673-6.
• Heisel O, Heisel R, Balshaw R, Keown P. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant 2004;4:583-95.
• Webster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ 2005;331:810.
• Heisel O, Heisel R, Balshaw R, Keown P. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant 2004;4:583-95.
• Vincenti F, Friman S, Scheuermann E, Rostaing L, Jenssen T, Campistol JM, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007;7:1506-14.
• van Duijnhoven EM, Christiaans MH, Boots JM, Nieman FH, Wolffenbuttel BH, van Hooff JP. Glucose metabolism in the first 3 years after renal transplantation in patients receiving tacrolimus versus cyclosporine-based immunosuppression. J Am Soc Nephrol 2002;13:213-20.
• Johnston O, Rose CL, Webster AC, Gill JS. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 2008;19:1411-8.
• Eckel RH. Mechanisms of the components of the metabolic syndrome that predispose to diabetes and atherosclerotic CVD. Proc Nutr Soc 2007;66:82-95.
• Van Laecke S, Van Biesen W, Verbeke F, De Bacquer D, Peeters P, Vanholder R. Posttransplantation hypomagnesemia and its relation with immunosuppression as predictors of new-onset diabetes after transplantation. Am J Transplant 2009;9:2140-9.
• Rodrigo E, Fernández-Fresnedo G, Valero R, Ruiz JC, Piñera C, Palomar R, et al. New-onset diabetes after kidney transplantation: risk factors. J Am Soc Nephrol 2006;17:291-5.
• Valderhaug TG, Hjelmesaeth J, Rollag H, Leivestad T, Rİislien J, Jenssen T, et al. Reduced incidence of new- onset posttransplantation diabetes mellitus during the last decade. Transplantation 2007;84:1125-30.
• Davidson J, Wilkinson A, Dantal J, Dotta F, Haller H, Hernández D, et al. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation 2003;75:3-24.
• Therasse A, Wallia A, Molitch ME. Management of post- transplant diabetes. Curr Diab Rep 2013;13:121-9.
• Hecking M, Haidinger M, Döller D, Werzowa J, Tura A, Zhang J, et al. Early basal insulin therapy decreases new-onset diabetes after renal transplantation. J Am Soc Nephrol 2012;23:739-49.